Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)
Status:
Recruiting
Trial end date:
2022-06-06
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess efficacy, safety and tolerability of treatment with
zibotentan and dapagliflozin in combination and alone, compared with placebo in participants
with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20
and 60 mL/min/1.73^2.